Riociguat - Bayer
Alternative Names: Adempas; BAY-32521; BAY-63-2521Latest Information Update: 05 Nov 2023
At a glance
- Originator Bayer
- Class 2 ring heterocyclic compounds; Antifibrotics; Carbamates; Diamines; Fluorobenzenes; Pyrazoles; Pyridines; Pyrimidines; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pulmonary arterial hypertension; Pulmonary hypertension
- Phase II Cystic fibrosis; Systemic scleroderma
- No development reported Raynaud's disease
Most Recent Events
- 22 Feb 2023 No development reported - Phase-III for Pulmonary hypertension in Sweden, Greece, Ireland, Netherlands, United Kingdom, Spain, Slovakia, Portugal, Poland, Italy, Germany, Denmark, Czech Republic, Belgium, Austria, Thailand (PO) (Bayer pipeline, February 2023)
- 17 Feb 2021 No development reported - Phase-II for Raynaud's disease in Germany (PO) (Bayer website, February 2020)
- 08 Sep 2020 Efficacy and safety data from the phase III PATENT-1 trial in Pulmonary arterial hypertension release by Bayer